Solid Biosciences price target lowered to $10 from $15 at Barclays

Barclays lowered the firm’s price target on Solid Biosciences (SLDB) to $10 from $15 and keeps an Overweight rating on the shares. The company’s Q1 report was largely incremental, with continued pipeline progress, the analyst tells investors in a research note.